Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
Outline of Final Research Achievements |
An optimal protocol of transcatheter arterial embolization for tendinopathy was investigated. While transcatheter arterial embolization using embosphere showed necrosis and micro abscess at the skin, imipenem/cilastatin sodium did not show any adverse event. Therefore, imipenem/cilastatin sodium can be safely used for the transcatheter arterial embolization for tendinopathy.
|